Actively Recruiting
Randomized Trial of Radiotherapy Plus Standard Therapy for Advanced Non-Small Cell Lung Cancer
Led by Trans Tasman Radiation Oncology Group · Updated on 2026-10-23
420
Participants Needed
6
Research Sites
313 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating metastatic non-small cell lung cancer NSCLC, a leading cause of cancer death with limited survival despite current drug therapies. This study evaluates whether adding radiotherapy to the primary lung tumor alongside standard drug treatment can reduce cancer spread, improve survival, enhance quality of life, and be cost-effective. The trial is a phase III randomized controlled study involving multiple expert teams and patient input, aiming to provide definitive answers for this critical medical need. Participants will receive either standard systemic chemotherapy alone or combined with highly precise radiotherapy targeting the primary lung tumor. Radiotherapy approaches include advanced techniques such as IMRT or VMAT, with several dosing schedules allowed, including 50Gy in 20 fractions, 40Gy in 15 fractions, or 35Gy in 5 fractions. The study leverages existing lung cancer registries across multiple sites to facilitate access and rapid adoption if successful. During the trial, participants will be monitored over several years with evaluations including overall survival up to five years post-recruitment, thoracic toxicity assessments, progression-free and cancer-specific survival, quality of life questionnaires, and economic analyses. Follow-up involves regular clinical assessments aligned with the study timeline to track treatment effects and safety. The total study duration extends to the end of 2036, providing comprehensive long-term data on outcomes and tolerability.
CONDITIONS
Brief Title
Primary Radiotherapy In MEtastatic Lung Cancer
Research Team
P
PRIME-Lung CRA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here